Affirm stock soars as Q1 earnings smash expectations, guidance lift
Investing.com - Raymond James has reiterated its Strong Buy rating and $45.00 price target on Sionna Therapeutics (NASDAQ:SION) following the company’s third-quarter 2025 update. The $45 target represents a 37% upside from the current price of $32.86, aligning with the broader analyst consensus that remains bullish with a 1.29 recommendation score (where 1 is Strong Buy).
Sionna Therapeutics is currently conducting two studies with its first-in-class NBD1 stabilizers. The first is a Phase 2a proof-of-concept study called PreciSION, which evaluates SION-719 as an add-on to Trikafta in cystic fibrosis patients. With a market capitalization of $1.57 billion, Sionna maintains a strong financial position, holding more cash than debt on its balance sheet according to InvestingPro data.
The PreciSION study aims to demonstrate that SION-719 is safe and well-tolerated while significantly improving CFTR function. Success would be defined as a reduction of ≥10 mmol/L in sweat chloride, which would translate to approximately a 3-point improvement in ppFEV1, a measure of lung function.
The second study involves healthy volunteers testing SION-451 in proprietary dual combinations with SION-2222 and SION-109. From this study, Sionna plans to advance one doublet into studies with cystic fibrosis patients.
Both the PreciSION and healthy volunteer doublet studies are expected to report topline data in mid-2026, with Raymond James noting they "continue to like the set-up into initial POC data next year."
In other recent news, Sionna Therapeutics has reported promising results from its Phase 1 clinical trials for its cystic fibrosis drug candidates, SION-719 and SION-451. The company announced that these first-in-class nucleotide binding domain 1 (NBD1) stabilizers were generally well tolerated and exceeded target exposure levels in trials involving over 200 healthy volunteers. Additionally, Sionna has initiated a Phase 2a proof-of-concept trial for SION-719 in combination with the standard treatment Trikafta, marking the first clinical evaluation of an NBD1 stabilizer in cystic fibrosis patients. Meanwhile, Freedom Capital Markets has begun coverage on Sionna Therapeutics with a Buy rating and a $38.00 price target, reflecting optimism about the company’s innovative approach. RBC Capital also initiated coverage with a Sector Perform rating and a $22.00 price target, noting the potential for Sionna’s CFTR modulators to establish the company as a significant player in the cystic fibrosis field. In another development, Sionna has started a Phase 1 trial to evaluate its novel CF treatment combinations, including SION-451, in dual combinations with SION-2222 and SION-109. This trial aims to assess the safety, tolerability, and pharmacokinetics of these combinations in healthy volunteers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.